Research programme: antisense obesity therapies - Isis Pharmaceuticals
Alternative Names: JNK1 antisense inhibitors; mDIC antisense inhibitorsLatest Information Update: 11 Feb 2011
At a glance
- Originator Isis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Dicarboxylic acid transporter inhibitors; Genetic transcription inhibitors; Mitogen-activated protein kinase 8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 03 Jul 2007 Preclinical trials in Obesity in USA (unspecified route)